The present invention relates to an anti-human ±9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human ±9 integrin； a hybridoma cell that produces the monoclonal antibody； a method for producing the monoclonal antibody； a method for producing the hybridoma cell； a therapeutic agent comprising the anti-human ±9 integrin antibody； a diagnostic agent comprising the human ±9 integrin antibody； and a method for screening for a compound that inhibits the activity of human ±9 integrin.
